H.C. Wainwright initiated coverage of Shattuck Labs (NASDAQ:STTK) with a “buy” rating and price target of $28. The stock closed at $3.84 on April 29. To overcome the shortcomings of current immunomodulatory cancer...
The efficacy endpoint of First Wave BioPharma’s (NASDAQ:FWBI) Phase 2 RESERVOIR trial with FW-COV did not demonstrate statistical significance, compared to placebo, in removing the SARS-CoV-2 virus from the digestive...
H.C. Wainwright launched coverage of Vera Therapeutics (NASDAQ:VERA) with a “buy” rating and $35 price target. The stock closed at $20 on April 29. Vera is a clinical-stage biotech company focused on developing disease...
Shishir Sinha Qualigen Therapeutics (NASDAQ:QLGN) appointed Shishir Sinha, the company’s newly promoted SVP and current COO, to lead its diagnostics division, FastPack. “With the return of the sales and...
Annovis Bio (NYSE:ANVS) entered a cooperative research and development agreement with the NIH’s National Institute on Aging to develop pharmacodynamic biomarkers for buntanetap, focusing on isolating brain-derived...
Analysts for SVB Securities and BTIG downgraded Accolade (NASDAQ:ACCD) after the company reduced the growth of its fiscal 2023 guidance to 15% year-over-year from 25% and the loss of Comcast as Accolade’s flagship...
Closely held PharmaJet presented new research at the World Vaccine Congress about clinical studies across multiple vaccine and therapeutic development programs that have incorporated its needle-free delivery systems...
BTIG upgraded Acutus Medical (NASDAQ:AFIB) to “buy” from “neutral” with a price target of $2, after the company announced a debt refinancing and the sale of its left-heart access product portfolio that should extend its...
Dr. Donald Hillebrand Sigyn Therapeutics (OTC:SIGY) appointed Dr. Donald Hillebrand, M.D., to its scientific advisory board. Dr. Hillebrand is the associate medical director of liver transplantation at Saint...
SVB Securities launched coverage of Opthea (NASDAQ:OPT) with an “outperform” rating and $25 price target. The stock closed at $5.71 on April 25. Opthea is a clinical-stage biotechnology company focused on developing...
The FDA rejected Ampio Pharmaceuticals’ (NYSE American:AMPE) proposed modified intent-to-treat (mITT) population as the primary analysis population for evaluating efficacy in the AP-013 trial, and the acceptability of...
Maxim Group initiated coverage of Processa Pharmaceuticals (NASDAQ:PCSA) with a “buy” rating and $9 price target. The stock closed at $2.87 on April 18. Processa is a clinical-stage company developing therapies for...